Springs of Life Zimbabwe welcomes Lenacapavir rollout, calls for decriminalisation and justice for sex workers
Staff Reporter AS Zimbabwe joins the world in commemorating International Sex Workers’ Day, Springs of Life Zimbabwe, a sex worker-led human rights organisation, has welcomed the prioritisation of Lenacapavir, a long-acting injectable HIV prevention drug, while urging urgent reforms to ensure legal protection, dignity, and full access to healthcare for sex workers. The organisation said
Read More
Zimbabwe Targets 46,000 Lenacapavir Users As Demand For HIV Prevention Injection Grows
Michael Gwarisa Zimbabwe is set to significantly expand access to Lenacapavir, the long-acting injectable HIV prevention drug, after securing additional financial support from the Global Fund through the United States Department of State, a development expected to strengthen HIV prevention efforts among high-risk populations. The new support will see an additional 43,000 doses added to
Read More
Mozambique Rolls Out Lenacapavir for HIV Prevention
 Michael Gwarisa Mozambique yesterday joined other African countries that have introduced and added Lenacapavir, a long-acting injectable HIV prevention drug, into their biomedical prevention methods. Other countries that have introduced the HIV prevention drug include Eswatini, Kenya, Lesotho, Nigeria, South Africa, Uganda, Zambia, and Zimbabwe. In Mozambique, the official launch was hosted at the
Read More
PEPFAR, Global Fund Expand Lenacapavir Access to Reach 3 Million in HIV Prevention Push
Michael Gwarisa Global efforts to scale up access to a groundbreaking HIV prevention injection have received a major boost after PEPFAR and The Global Fund announced additional investment in Gilead Sciences’ long-acting drug, lenacapavir, with the aim of expanding protection to millions at risk. The new commitment will support access for up to an additional
Read More
Zimbabwe’s Medicines Regulatory Body Registers Lencapavir
By Michael Gwarisa The Medicines Control Authority of Zimbabwe (MCAZ) has announced the expedited approval of Lenacapavir, an innovative long-acting medicine for pre exposure prophylaxis (PrEP) to prevent HIV-1 infection. The MCAZ Director-General, Mr. Richard T. Rukwata, said “the rapid approval of Lenacapavir reflects the Authority’s dedication to accelerating access to trusted, high-quality health products
Read MoreZimbabwe to Prioritise Local Funding in New HIV Strategy
By Michael Gwarisa Zimbabwe is set to begin developing its fifth Zimbabwe National HIV and AIDS Strategic Plan (ZNASP V), which will guide the country’s HIV response from 2026 to 2030. The forthcoming strategy follows the successful implementation of ZNASP IV, which runs until 2025 and has seen major progress in the fight against HIV.
Read MoreSuspended HIV Services Resume in Masvingo as CAB-LA, Vaginal Ring Return for Key Populations
By Michael Gwarisa, recently in Masvingo For the past 12 months, Wellington*, a 41-year-old Masvingo man who has sex with men (MSM) and a male sex worker, has relied on oral Pre-Exposure Prophylaxis (PrEP) to reduce his risk of HIV infection. He has also used condoms and occasionally Post-Exposure Prophylaxis (PEP). At the start of
Read More
Suspended HIV Services Resume in Masvingo as CAB-LA, Vaginal Ring Return for Key Populations
By Michael Gwarisa, recently in Masvingo For the past 12 months, Wellington*, a 41-year-old Masvingo man who has sex with men (MSM) and a male sex worker, has relied on oral Pre-Exposure Prophylaxis (PrEP) to reduce his risk of HIV infection. He has also used condoms and occasionally Post-Exposure Prophylaxis (PEP). At the start of 2025,
Read MoreFDA approves twice-a-year injection for HIV prevention
CNN — A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV. Gilead Sciences, maker of the drug, announced that a twice-a-year injection of lenacapavir has been approved in the United States for HIV prevention under the brand name Yeztugo.
Read MoreCAB-LA Enjoys High Continuity Rates Among PrEP Users In Zimbabwe
By Michael Gwarisa The recently introduced long-acting cabotegravir (CAB-LA) for HIV prevention has seen more users returning to get the second dose post their first jab, with data showing that the injectable drug has recorded a continuity rate over 90% since roll out in April, 2024. Currently, the Injectable PrEP is being administered in PrEP
Read More